Skip to Content

Teleflex Inc TFX

Rating as of

Morningstar’s Analysis

Currency in USD
Is it the right time to buy or sell?
Find out with Morningstar Premium
Is it the right time to buy or sell?
Find out with Morningstar Premium

1-Star Price


5-Star Price


Economic Moat


Capital Allocation


Rebounding Surgeries and Ongoing UroLift Adoption Lift Teleflex Above Prepandemic Baseline in Q2

Aaron Degagne Equity Analyst

Analyst Note

| Aaron Degagne |

Teleflex reported good second-quarter results, with constant-currency sales growth of 21% and adjusted earnings per share growth 74% on a favorable comparable to last year. While Teleflex slightly exceeded our expectations, this was offset by the implementation of a weighted average U.S. corporate tax rate of 26% in our model, and we maintain our $183 fair value estimate and no-moat rating.

Read Full Analysis

Company Profile

Business Description

Teleflex is a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices primarily in the bloodstream/vascular and surgical areas. The firm reports results across seven segments: vascular access (26% of 2020 sales), interventional (15%), surgical (13%), anesthesia (12%), interventional urology (13%), original-equipment manufacturing (7%), and all other (14%). Geographic exposure for the business is primarily in the U.S., which accounts for 60% of revenue, with international markets making up the remainder.

550 East Swedesford Road, Suite 400
Wayne, PA, 19087
T +1 610 225-6800
Sector Healthcare
Industry Medical Instruments & Supplies
Most Recent Earnings Jun 30, 2021
Fiscal Year End Dec 31, 2021
Stock Type Classic Growth
Employees 14,000